

UPDATE OF 23 SEPTEMBER 2022

(most recently added papers are marked in blue)

<p>Coordinated by:</p> <p><i>ANRS-EID/I3M: Erica Telford & Eric D'Ortenzio</i></p> <p>Documented by (until Sept. 2020): <i>Inserm- Collective Expertise Unit: Bénédicte Varignon & Laurent Fleury</i></p>	<p>Redaction Committee :</p> <p><i>ANRS-Emerging Infectious Diseases: Claire Brugerolles; Guia Carrara; Mario Delgado-Ortega; Inmaculada Ortega-Perez; Erica Telford</i></p> <p>With a precious contribution from:</p> <p>• Former members of the redaction committee: <i>Eric D'Ortenzio; Evelyne Jouvin-Marche; Boris Lacarra; Claire Madelaine; Xyomara Chavez-Pacheco; Oriane Puéchal; Renaud Vatrinet</i> • <i>Inserm- Department of Partnerships and External Relations (DPRE)</i> • <i>Inserm-USA office</i> • <i>The MODCOV19 Team</i></p>
---	--

Journal	Date	Title (Hyperlink)	Authors and doi	Country	Field of expertise
Clin Infect Dis.	2022.09.22	Effectiveness of mRNA-1273 vaccine booster against COVID-19 in immunocompetent adults	Florea A., et al. https://doi.org/10.1093/cid/ciac785	USA	Vaccines
eClinical Medicine	2022.09.21	Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial	Kalfon P., et al. https://doi.org/10.1016/j.eclinm.2022.101663	France	Clinics
Lancet Infect Dis.	2022.09.21	Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study	Carazo S., et al. https://doi.org/10.1016/S1473-3099(22)00578-3	Canada	Vaccines/Variants
Lancet Child Adolesc Health	2022.09.21	Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study	Kracalik I., et al. https://doi.org/10.1016/S2352-4642(22)00244-9	USA	Clinics
NEJM	2022.09.21	IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination	Thurner L., et al. https://doi.org/10.1056/NEJMc2205667	Germany	Clinics
Science Adv.	2022.09.21	SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression	Hashimoto R., et al. https://doi.org/10.1126/sciadv.abo6783	Japan	Virology
Science Immunol.	2022.09.20	Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5	Muik A., et al. https://doi.org/10.1126/sciimmunol.ade2283	Germany	Immunology
Clin Infect Dis.	2022.09.20	Associations of Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA-1273 Vaccine in COVE and TeenCOVE Trials	Siangphoe U., et al. https://doi.org/10.1093/cid/ciac780	USA	Vaccines
JAMA	2022.09.20	Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19	Arabi Y. M., et al., https://doi.org/10.1001/jama.2022.15599	Saudi Arabia	Clinics
Clin Microbiol Infect	2022.09.19	Association between low response to rubella vaccination and reduced anti-SARS-CoV-2 immune response after vaccination with BNT162b2: A cross-sectional study	Nakaharai K., et al., https://doi.org/10.1016/j.cmi.2022.09.007	Japan	Vaccines

PNAS	2022.09.19	Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein	Yang K., et al. https://doi.org/10.1073/pnas.2210990119	Finland / USA	Therapeutics
Clin Infect Dis.	2022.09.18	Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the Omicron variants: A retrospective cohort study using large-scale population-based registries in Japan	Ono S., et al. https://doi.org/10.1093/cid/ciac763	Japan	Vaccines
J Infect Dis.	2022.09.17	Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch	Razonable R.R., et al. https://doi.org/10.1093/infdis/jiac346	USA	Therapeutics
NEJM	2022.09.16	A Bivalent Omicron-Containing Booster Vaccine against Covid-19	Chalkias S, et al. https://doi.org/10.1056/NEJMoa2208343	USA	Vaccines
BioRxiv	2022.09.16	Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies	Sheward D. J., et al., https://doi.org/10.1101/2022.09.16.508299	Sweden	Variants
BMJ	2022.09.15	A living WHO guideline on drugs for covid-19	Agarwal A., et al. https://doi.org/10.1136/bmj.m3379	International	Therapeutics
Science	2022.09.15	The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance	Tegally H., et al. https://doi.org/10.1126/science.abq5358	International	Public Health / Epidemiology
Lancet	2022.09.14	The Lancet Commission on lessons for the future from the COVID-19 pandemic	Sachs J.D., et al. https://doi.org/10.1016/S0140-6736(22)01585-9	International	Vaccines
eBioMedicine	2022.09.15	Protection against SARS-CoV-2 transmission by a parenteral prime—Intranasal boost vaccine strategy	Christensen D., et al. https://doi.org/10.1016/j.ebiom.2022.104248	Denmark / Sweden	Vaccines
Lancet Infect Dis.	2022.09.14	Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study	Amir O., et al. https://doi.org/10.1016/S1473-3099(22)00527-8	Israel	Vaccines
NEJM	2022.09.14	Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection	Havervall S., et al. https://doi.org/10.1056/NEJMc2209651	Sweden	Immunology
NEJM	2022.09.14	Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine	Lane S., et al. https://doi.org/10.1056/NEJMc2210813	Argentina / UK	Vaccines
Cell	2022.09.14	Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants including BA.4 and BA.5	Kimura I., et al. https://doi.org/10.1016/j.cell.2022.09.018	Japan	Variants
NEJM	2022.09.14	Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa	Collie S., et al. https://doi.org/10.1056/NEJMc2210093	South Africa	Vaccines
Ann Intern Med.	2022.09.13	Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore	Tan C.Y., et al. https://doi.org/10.7326/M22-2042	Singapore	Vaccines
Lancet Infect Dis.	2022.09.09	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial	Hardt K., et al. https://doi.org/10.1016/S1473-3099(22)00506-0	Belgium	Vaccines
Clin Microbiol Infect.	2022.09.09	Evaluating the Efficacy and Safety of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 Spike Protein Vaccine: A Phase 3 Randomized Placebo-Controlled Trial	Tabarsi P, et al. https://doi.org/10.1016/j.cmi.2022.09.001	Australia / Iran	Vaccines

JAMA	2022.09.08	<u>Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals</u>	Kachikis A., et al. https://doi.org/10.1001/jamanetworkopen.2022.30495	Israel / USA	Vaccines
Nature Com	2022.09.08	<u>The impact of repeated rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2</u>	Menkir T.F., et al. https://doi.org/10.1038/s41467-022-32640-2	UK / USA	Public health / Epidemiology
PNAS	2022.09.08	<u>A single-administration therapeutic interfering particle reduces SARS-CoV-2 viral shedding and pathogenesis in hamsters</u>	Chaturvedi S., et al. https://doi.org/10.1073/pnas.2204624119	USA	Therapeutics
Science Transl Med.	2022.09.07	<u>Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models</u>	Hajnik R.L., et al. https://doi.org/10.1126/scitranslmed.abq1945	USA	Vaccines
Lancet Respir Med.	2022.09.07	<u>Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial</u>	Vlaar A.P.J., et al. https://doi.org/10.1016/S2213-2600(22)00297-1	International	Therapeutics
BMJ	2022.09.07	<u>Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial</u>	Brunvoll S.H., et al. https://doi.org/10.1136/bmj-2022-071245	Norway	Therapeutics
Clover	2022.09.06	<u>Clover's COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine</u>	https://ir.cloverbiopharma.com/news-releases/news-release-details/clovers-covid-19-vaccine-candidate-demonstrates-superior-booster	China	Press Release
Nature Med	2022.09.05	<u>Long-term cardiac pathology in individuals with mild initial COVID-19 illness</u>	Puntmann V.O., et al. https://doi.org/10.1038/s41591-022-02000-0	Germany	Long Covid
Lancet Infect Dis.	2022.09.05	<u>Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial</u>	Lazarus R., et al. https://doi.org/10.1016/S1473-3099(22)00502-3	UK	Vaccines
medRxiv	2022.08.31	<u>A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults</u>	Lien C.E., et al. https://doi.org/10.1101/2022.08.29.22279317	Taiwan	Vaccines